James Dahlman, PhD
Associate Professor and holder of the McCamish Foundation Early Career Professorship, Wallace H. Coulter Department of Biomedical Engineering, Georgia Tech University
Member, Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute
Biography
James Dahlman, PhD, is a chemical and bioengineer whose work lies at the interface of nanotechnology, genomics and gene editing.
Dr. Dahlman is interested in drug delivery, targeted in vivo gene editing, and using genomics to improve biomaterial design. He has designed and synthesized nanoparticles that efficiently deliver RNAs to the lung and heart. These nanoparticles can deliver multiple RNAs at once, and can simultaneously knockdown five genes concurrently in vivo. They have been used by over ten labs across the United States to study cancer, atherosclerosis, inflammation, emphysema, and pulmonary hypertension, and are being evaluated for clinical trials.
Dr. Dahlman received his PhD from MIT and Harvard Medical School in 2014, where he studied RNA delivery with Robert Langer and Daniel Anderson. He studied RNA design and gene editing as a post-doc with Feng Zhang at the Broad Institute.